[Thrombolytic therapy with urokinase--indications and results].
Urokinase is a potent fibrinolytic agent. Its good tolerance and the close correlation to the dosage render the treatment well governable and reduce the possible side effects. However, the comparatively high costs have to be taken into account. Up to now, urokinase is an indispensable tool for long-term lysis.
D001026:Coronary Artery Bypass / Q000009:adverse effects; D005176:Factor XIII / Q000032:analysis; D005340:Fibrinogen / Q000032:analysis; D005342:Fibrinolysis; D005500:Follow-Up Studies; D006331:Heart Diseases / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy; D010958:Plasminogen / Q000032:analysis; D012306:Risk; D013927:Thrombosis / Q000188:drug therapy* / Q000517:prevention & control; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use*
D005340:Fibrinogen; D010958:Plasminogen; D005176:Factor XIII; D014568:Urokinase-Type Plasminogen Activator
Thrombolytische Therapie mit Urokinase--Indikationen und Ergebnisse.